Drug Type Small molecule drug |
Synonyms Amesergide (USAN/INN), LY 237733, LY-237733 |
Target |
Action antagonists |
Mechanism 5-HT2A receptor antagonists(Serotonin 2a (5-HT2a) receptor antagonists) |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
License Organization- |
Drug Highest PhaseDiscontinuedPhase 2 |
First Approval Date- |
Regulation- |
Molecular FormulaC25H35N3O |
InChIKeyKEMOOQHMCGCZKH-JMUQELJHSA-N |
CAS Registry121588-75-8 |
| KEGG | Wiki | ATC | Drug Bank |
|---|---|---|---|
| D02893 | Amesergide | - | - |
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Erectile Dysfunction | Phase 2 | United States | - | |
| Premature Ejaculation | Phase 2 | United States | - | |
| Anxiety Disorders | Preclinical | United States | 01 Jan 1992 | |
| Depressive Disorder | Preclinical | United States | 01 Jan 1992 | |
| Migraine Disorders | Preclinical | United States | 01 Jan 1992 | |
| Schizophrenia | Preclinical | United States | 01 Jan 1992 |





